Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Brief Summary

The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.

Intervention / Treatment

  • Drug: Low Dose Psilocybin
  • Drug: Placebo
  • Drug: Medium Dose Psilocybin

Condition or Disease

  • Major Depressive Disorder

Phase

Study Design

Study type: Interventional
Status: Active, not recruiting
Study results: No Results Available
Age: 18 Years to 65 Years   (Adult, Older Adult)
Enrollment: 18 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Jun 30, 2018
Primary Completion: Jun 01, 2022
Completion Date: Apr 01, 2023
Study First Posted: Jun 13, 2018
Results First Posted: Aug 30, 2020
Last Updated: Nov 12, 2021

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

In this placebo-controlled, blinded study, individuals with depression will participate in 2 experimental sessions approximately 4 weeks apart during which they will receive two of the following three interventions: 1) placebo, 2) low dose psilocybin (0.1 mg/kg), and 3) medium dose psilocybin (0.3 mg/kg).

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 65

More Details

NCT Number: NCT03554174
Other IDs: 2000022394
Study URL: https://ClinicalTrials.gov/show/NCT03554174
Last updated: Jun 16, 2022